

Special Issue

Heterocyclic Chemistry in Drug Design

Message from the Guest Editor

Currently, the available chemical space includes more than 100 million organic compounds, mainly related to a limited set of classes and types. Meanwhile, modern drug design trends require the development of synthetic approaches to equally and diversely fill the chemical space as a source of drug-like structures. These trends have affected heterocyclic chemistry as the main "supplier" of drug-like molecules (all top 10 brand name small molecule drugs contain heterocyclic moieties), which stipulate strict requirements, both for bioactive compounds, as well as the methods of their synthesis. Thus, synthetic methods should provide a diversity of molecular architectonics, high chemo-, regio- and stereoselectivity, as well as atomic efficiency, in order to be ecologically and economically justified. The simultaneous implementation of these requirements is a rather difficult task, and research aimed at achieving a certain balance between them is relevant. As heterocycles are common fragments in the vast majority of marketed drugs, they obviously have a central role in modern drug design. In this Special Issue, we will focus on recent advances in heterocyclic chemistry in drug design.

Guest Editor

Prof. Dr. Roman B. Lesyk
Department of Pharmaceutical, Organic and Bioorganic Chemistry,
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Deadline for manuscript submissions

closed (28 February 2019)



Scientia Pharmaceutica

an Open Access Journal
Published by MDPI

Impact Factor 2.5
CiteScore 4.6



mdpi.com/si/18294

Scientia Pharmaceutica
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
scipharm@mdpi.com

[mdpi.com/journal/
scipharm](https://mdpi.com/journal/scipharm)





Scientia Pharmaceutica

an Open Access Journal
Published by MDPI

Impact Factor 2.5
CiteScore 4.6



[mdpi.com/journal/
scipharm](https://mdpi.com/journal/scipharm)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Helmut Viernstein
Division of Pharmaceutical Technology and Biopharmaceutics,
University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), Embase,
CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 22.8 days after
submission; acceptance to publication is undertaken in 3.1
days (median values for papers published in this journal in
the second half of 2025).